CSHL 2013 Conference on RNA and Oligonucleotide Therapeutics

To identify a therapeutic oligonucleotide with the right drug-like properties, a large number of oligonucleotides are usually screened. However, many more oligonucleotides can be designed against a target than can practically be screened (see previous blog). So how should we select oligonucleotides for a screening campaign among the vast number of possibilities?

In early April, the Cold Spring Harbor Laboratory will host a conference on RNA and oligonucleotide therapeutics. Some of the research done in COAT to address this issue will be presented at the conference.

Morten will be giving a talk, where he demonstrate that the sequence-nature of oligonucleotides, combined with data from a large number of screening

campaigns, may contain so much information that a systematic analysis can yield predictive models of affinity, potency, specificity, and toxicity. Two examples of this approach will be presented in-depth on posters. Lykke will present a kinetic model of enzyme recruiting oligonucleotides, and demonstrate that it predicts an optimal binding affinity between oligonucleotide and RNA target. This explains why shorter and less affine oligonucleotides may sometimes be more potent. And Peter will present how the hepatotoxic potential of oligonucleotides can be predicted from their sequence and modification pattern using machine learning.

All abstracts for the meeting can be seen here. We look forward to the talk by our colleague Dr. Susanna Obad from Santaris Pharma, presenting data on the treatment of hepatitis C infected patients with the antimiR oligonucleotide Miravirsen.

We are excited to participate and contribute with some of our research at the meeting. See you there!

Posted in Conferences, Oligoinformatics

Leave a Reply